A Failed Product-Identifier Scan and a Class II Recall on the Same Day
A community pharmacy receives a case of apixaban 5 mg from its primary wholesaler at 0930. While scanning the 2D DataMatrix product identifiers at receipt, the receiving technician finds one carton whose serialized identifier will not verify in the approved verification system; the system returns an error rather than a verified status. Separately, the pharmacy's recall inbox received a Class II recall notice that morning covering apixaban 2.5 mg from the same manufacturer, lot-specific. An established patient on apixaban 5 mg is due for a refill at 1400 today, and the pharmacy currently has 24 verified tablets of 5 mg and 10 tablets from the questionable carton in the will-call area.
1. What do you do with the carton that failed verification, in order and with time frames? What may you not do with it?
Read the worked answer
- Stop and quarantine immediately (within the pharmacy's 30-minute standard): move the carton to a locked, clearly labeled 'Do Not Dispense - Suspect Product' area, physically separated from saleable stock. Do not put any of it in will-call.
- Treat it as a suspect product under DSCSA - a product with a reasonable probability of being illegitimate - until an investigation resolves it. Suspect product is not saleable and is not returnable to the supply chain as saleable.
- Document: date/time of detection, serial number and lot, quantity, who detected it, the verification system error text, and the quarantine location.
- Investigate and notify the trading partner: contact the wholesaler from whom it was purchased and the manufacturer as directed, provide the product identifier and lot, and ask them to investigate. Do not attempt to 're-scan until it works.'
- If the investigation determines the product is illegitimate (counterfeit, diverted, stolen, fraudulent, or unfit), notify FDA via Form 3911 within 24 hours and notify the immediate trading partners in the transaction within the same 24-hour window. Retain records - DSCSA transaction and investigation records must be kept for 6 years.
- What you may not do: dispense it, transfer it to another pharmacy, return it to the wholesaler for resale, or discard it before the investigation closes and the disposition is authorized.
2. How does the Class II recall on the 2.5 mg product change your actions, and how do you ensure the 1400 patient gets therapy?
Read the worked answer
The recall is a separate event from the suspect carton and has its own workflow. Class II means exposure may cause temporary or medically reversible harm with a remote probability of serious harm - for an anticoagulant, a subpotent or superpotent lot is a real clinical hazard, so urgency is justified.
Recall steps:
- Read the notice for the exact lot numbers, whether the action is pharmacy level or patient level, and the return/credit instructions.
- Immediately pull all stock of the affected NDC and lots, including anything in the will-call bins and the returns area; reconcile quantities on hand against the notice and against dispensing records.
- Quarantine per the recall instructions; do not return product except as the notice directs; photograph and document.
- If any affected lots were dispensed, pull those patients' records and notify patients and prescribers at the level the notice requires (a 2.5 mg patient on apixaban must not simply be told to skip doses).
Getting the 1400 patient their refill: keep the two issues separate - this patient takes 5 mg, which is not the recalled strength, so a verified, unaffected 5 mg supply can be dispensed. Confirm the 24 verified tablets are from lots not named in any notice, dispense what is verified, and order replacement stock from the wholesaler with a documented call. If verified 5 mg supply were insufficient, arrange an immediate transfer or a short supply from a nearby pharmacy and contact the prescriber - a delayed anticoagulant refill is a thromboembolic risk, so the patient must leave with therapy today.
3. A colleague asks why you are treating these two events differently. Explain the distinction and what documentation each requires.
Read the worked answer
Different legal triggers, different obligations:
| Suspect product / failed verification | Recall | |
|---|---|---|
| Origin | DSCSA transaction and product-identifier verification at receipt; a question about legitimacy | Manufacturer or FDA action removing defined lots from the market |
| Trigger for action | Any verification failure or illegitimate-product suspicion | Receipt of the recall notice, matched against inventory |
| Core actions | Quarantine, investigate, notify trading partners; FDA Form 3911 within 24 h if determined illegitimate | Quarantine named lots, reconcile inventory, follow return/credit directions, notify patients/prescribers at the level specified |
| Records | Serial/lot, verification error, investigation trail, notifications; retained 6 years | Notice copy, lots and quantities removed, dispensing history review, patient notification log |
Practical rule: a recall does not require an FDA Form 3911, and a failed scan is not a recall. Both, however, require the same discipline - remove the product from saleable stock before anything else, document contemporaneously, and never let an inventory problem become a patient-safety problem. Keep the two files separate so a future auditor or inspector can follow each chain independently.